Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims

Claim 1 (previously presented) A method of treating a degenerative disease in a subject in need thereof, comprising the step of inhibiting γ-GT activity in said subject.

Claim 2 (currently amended) The method of claim 1, wherein said degenerative disease is a chronic renal disease ~~or an inner ear degenerative condition or injury~~.

Claim 3 (previously presented) The method of claim 2 wherein said chronic renal disease is ROS induced.

Claim 4 (previously presented) The method of claim 3, wherein said chronic renal disease is selected from the group consisting of focal glomerulosclerosis, segmental glomerulosclerosis, minimal change nephrosis, inflammatory glomerulopathies, diabetic nephropathy and autoimmune glomerulopathies.

Claim 5 (withdrawn) The method of claim 2, wherein said inner ear injury is ROS induced.

Claim 6 (withdrawn) The method of claim 5, wherein said ROS induced inner ear injury is sensineural deafness induced by age, physiological status, metabolic status or drugs.

Claim 7 (withdrawn) The method of claim 6, wherein said drugs are selected from aminoglycosides or cisplatin derivatives.

Claim 8 (withdrawn) The method of claim 2, wherein said inner ear degenerative condition is otosclerosis.

Claim 9 (currently amended) The method of any one of claims 1 to ~~8~~4, wherein said γ-GT inhibitor is selected from the group consisting of AT-125 (Acivicin) or its derivatives~~, γ-glutamyl amino acids and peptides of the general formula γ-Glu-XY, pepticles of the general formula (CysGlyX), peptidomimetic glutathion analogues, compounds or derivatives of the type L-2-amino-4-boronobutanoic acid (ABBA), and anilides, such as γ-glutamyl-7-amido-4-methylcoumarin (γ-Glu-AMC)~~.

Claim 10 (withdrawn) The method of claim 9, wherein X and Y stand for any naturally occurring aminoacid, a modified aminoacid, a oligopeptide or a polypeptide.